Kala Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 14.46 million compared to USD 32.94 million a year ago. Basic loss per share from continuing operations was USD 6.99 compared to USD 22.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.63 USD | +1.22% | -2.73% | -5.29% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.29% | 18.45M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023